Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma-Reference-Cited by-同舟云学术

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Published:2016-03-03 Issue:9 Volume:127 Page:1109-1116
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zweegman Sonja¹,van der Holt Bronno²,Mellqvist Ulf-Henrik³,Salomo Morten⁴,Bos Gerard M. J.⁵,Levin Mark-David⁶,Visser-Wisselaar Heleen²,Hansson Markus⁷,van der Velden Annette W. G.⁸,Deenik Wendy⁹,Gruber Astrid¹⁰,Coenen Juleon L. L. M.¹¹,Plesner Torben¹²,Klein Saskia K.¹³,Tanis Bea C.¹⁴,Szatkowski Damian L.¹⁵,Brouwer Rolf E.¹⁶,Westerman Matthijs¹⁷,Leys M. (Rineke) B. L.¹⁸,Sinnige Harm A. M.¹⁹,Haukås Einar²⁰,van der Hem Klaas G.²¹,Durian Marc F.²²,Mattijssen E. (Vera) J. M.²³,van de Donk Niels W. C. J.¹,Stevens-Kroef Marian J. P. L.²⁴,Sonneveld Pieter²⁵,Waage Anders²⁶

Affiliation:

1. Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;

2. Hemato Oncologie Volwassenen Nederland Data Center, Erasmus Medical Center Cancer Center, Rotterdam, The Netherlands;

3. Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gotheborg, Sweden;

4. Department of Hematology, Rigshospitalet, Copenhagen, Denmark;

5. Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands;

6. Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands;

7. Division of Hematology and Transfusion Medicine, Skane University Hospital, Lund, Sweden;

8. Department of Internal Medicine, Martini Ziekenhuis, Groningen, The Netherlands;

9. Department of Internal Medicine, Tergooi Ziekenhuizen, Blaricum, The Netherlands;

10. Center of Hematology, Karolinska Institute, Stockholm, Sweden;

11. Department of Internal Medicine, Isala, Zwolle, The Netherlands;

12. Department of Hematology, Vejle Hopital, Vejle, Denmark;

13. Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, The Netherlands;

14. Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, The Netherlands;

15. Department of Oncology, Hematology and Palliative Care, Førde Central Hospital, Førde, Norway;

16. Department of Internal Medicine, Reinier de Graaf Ziekenhuis, Delft, The Netherlands;

17. Department of Internal Medicine, Medisch Centrum Alkmaar, Alkmaar, The Netherlands;

18. Department of Internal Medicine, Maasstad Ziekenhuis, Rotterdam, The Netherlands;

19. Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands;

20. Department of Hematology, Stavanger University Hospital, Stavanger, Norway;

21. Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, The Netherlands;

22. Department of Internal Medicine, Tweesteden Ziekenhuis, Tilburg, The Netherlands;

23. Department of Internal Medicine, Rijnstate Ziekenhuis, Arnhem, The Netherlands;

24. Department of Genetics, Radboud University Medical Center, Nijmegen, The Netherlands;

25. Department of Hematology, Erasmus Medical Center Cancer Center, Rotterdam, The Netherlands; and

26. Department of Hematology, St Olavs Hospital and Norwegian University of Science and Technology and KG Jebsen Myeloma Research Center, Trondheim, Norway

Abstract

Key Points In a multicenter, randomized phase 3 trial, MPR-R was not superior over MPT-T with respect to response rate, PFS, and OS. Grade 3/4 hematologic toxicity requiring growth factor support occurred with MPR-R vs clinically significant neuropathy with MPT-T.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/9/1109/1395773/1109.pdf

Reference19 articles.

1. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.;Fayers;Blood,2011

2. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.;Facon;Lancet,2007

3. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.;Hulin;J Clin Oncol,2009

4. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.;Palumbo;Lancet,2006

5. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.;Wijermans;J Clin Oncol,2010

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy;Medical Oncology;2024-04-23

2. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review;Blood Cancer Journal;2024-01-25

3. Current trends and future prospects of drug repositioning in gastrointestinal oncology;Frontiers in Pharmacology;2024-01-04

4. Nitrogen mustards;Encyclopedia of Toxicology;2024

5. Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma;JAMA Network Open;2023-11-10